EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The CXCL13 Index as a Predictive Biomarker for Activity in Clinically Isolated Syndrome

Steven C Pike iD, Francesca Gilli, Andrew R Pachner

International Journal of Molecular Sciences · 04.07.2023 · 24 (13) · 11050

DOI: 10.3390/ijms241311050 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 04.07.2023. Verfasst von Steven C Pike und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Geisel School of Medicine at Dartmouth and Dartmouth Hitchcock Medical Center, Lebanon, NH 03756, USA. Hauptthemen laut MEDLINE: Multiple Sclerosis, Demyelinating Diseases. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hitchcock Foundation, Edgerton Fund:, Bornstein Research Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Multiple sclerosis (MS) is a clinically heterogenous disease. Currently, we cannot identify patients with more active disease who may potentially benefit from earlier interventions. Previous data from our lab identified the CXCL13 index (ICXCL13), a measure of intrathecal production of CXCL13, as a potential biomarker to predict future disease activity in MS patients two years after diagnosis. Patients with clinically isolated syndrome (CIS) or radiologically isolated syndrome (RIS) underwent a lumbar puncture and blood draw, and the ICXCL13 was determined. They were then followed for at least 5 years for MS activity. Patients with high ICXCL13 were more likely to convert to clinically definite MS (82.4%) compared to those with low ICXCL13 (10.0%). The data presented below demonstrate that this predictive ability holds true in CIS and RIS patients, and for at least five years compared to our initial two-year follow-up study. These data support the concept that ICXCL13 has the potential to be used to guide immunomodulatory therapy in MS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple SclerosisDemyelinating DiseasesHumansFollow-Up StudiesMagnetic Resonance ImagingBiomarkersDisease ProgressionChemokine CXCL13

Stichwörter der Autor:innen

B cellCXCL13clinically isolated syndromeinitial clinical demyelinating eventmultiple sclerosisradiologically isolated syndrome biomarker

Substanzen

BiomarkersCXCL13 protein, humanChemokine CXCL13

Autor:innen und Institutionen

  • Department of Neurology, Geisel School of Medicine at Dartmouth and Dartmouth Hitchcock Medical Center, Lebanon, NH 03756, USA.
  • Integrative Neuroscience at Dartmouth, Guarini School of Graduate and Advanced Studies, Hanover, NH 03755, USA.
  • Department of Epidemiology, Geisel School of Medicine at Dartmouth, Hanover, NH 03755, USA.

ORCID-Profile: Steven C Pike

Förderung

  • Hitchcock Foundation
  • Edgerton Fund:
  • Bornstein Research Fund
  • Diamond Endowment
  • Edgerton Fund
  • Burroughs Wellcome Fund Big Data

Zitieren

APA

Pike, S. C., Gilli, F., & Pachner, A. R. (2023). The CXCL13 Index as a Predictive Biomarker for Activity in Clinically Isolated Syndrome. International Journal of Molecular Sciences, 24(13), 11050. https://doi.org/10.3390/ijms241311050

Vancouver

Pike SC, Gilli F, Pachner AR. The CXCL13 Index as a Predictive Biomarker for Activity in Clinically Isolated Syndrome. International Journal of Molecular Sciences. 2023;24(13):11050. doi:10.3390/ijms241311050

BibTeX
@article{Pike2023,
  author = {Pike, Steven C and Gilli, Francesca and Pachner, Andrew R},
  title = {The CXCL13 Index as a Predictive Biomarker for Activity in Clinically Isolated Syndrome},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  volume = {24},
  number = {13},
  pages = {11050},
  doi = {10.3390/ijms241311050}
}
Kostenlos starten →